McDermott Advises Corteria Pharmaceuticals on the Closing of EUR 12 Million Seed Financing to Advance Portfolio Assets


McDermott Will & Emery advised Corteria Pharmaceuticals, a French biotechnology company specializing in the development of interceptive therapies for heart failure sub- populations, on the successful completion of its seed round financing, providing GBP 12 million. The financing provided by a pool of European investors (V-Bio Ventures, Omnes Capital and Invivo Capital) and led by Kurma Partners will allow Corteria Pharmaceuticals to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France).

Heart failure is still a prevalent concern despite current standards of care, affecting more than 60 million patients worldwide. Corteria’s R&D programs will address the full spectrum of heart failure decompensation and offer opportunities for developing transformative therapies for the treatment of worsening and acute decompensated heart failure.

The McDermott team that advised Corteria Pharmaceuticals comprised :

Emmanuel Trombe and Anthony Paronneau (partners) and Katya Ascher, (counsel), Lucie Martin and Ludivine Rabreau {associates) on corporate and licensing aspects.

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.